MedPath

Hypofractionated Radiation Therapy for Glioblastoma

Phase 2
Conditions
Glioblastoma Multiforme
Registration Number
NCT03212235
Lead Sponsor
Instituto do Cancer do Estado de São Paulo
Brief Summary

Notwithstanding major improvements in treatment modalities, the prognosis of patients with glioblastoma is poor. Hypofractionated radiation therapy as an alternative of the standard 6-week regimen could be an attractive approach as an effort to prevent tumor cell repopulation and reduction the total treatment period promoting patient comfort and convenience.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
58
Inclusion Criteria
  • Patients 18 to 70 years of age with newly diagnosed and histologically confirmed glioblastoma.
  • WHO performance status of 2 or less and adequate hematologic, renal, and hepatic function.
Exclusion Criteria
  • Prior diagnosis of cancer, unless disease free for > 3 years
  • Previous history of radiotherapy in the head and neck region (except initial larynx tumor - T1, T2 / N0M0).
  • Specific severe, active co-morbidities
  • Tumor located in the brainstem
  • Presence of leptomeningeal carcinomatosis
  • Multicentric tumor

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Overall survival24 months

From date of the start of treatment to date of death due to any cause.

Secondary Outcome Measures
NameTimeMethod
Progression-free survival24 months

The time between the start of treatment and tumor progression or death due to any cause.

Trial Locations

Locations (1)

Instituto do Cancer do Estado de São Paulo (ICESP) - FMUSP

🇧🇷

São Paulo, Sao Paulo, Brazil

Instituto do Cancer do Estado de São Paulo (ICESP) - FMUSP
🇧🇷São Paulo, Sao Paulo, Brazil
Gustavo N Marta, PhD
Contact
55+11+38934538
gustavo.marta@hc.fm.usp.br

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.